Panuveitis: Understanding Inflammation That Affects the Entire Eye
What Is Panuveitis?
Panuveitis is a condition in which inflammation affects every part of the uvea, the blood-rich inner layer that lines and nourishes the eye. Understanding how the uvea is structured helps explain why this condition can cause such wide-ranging symptoms and serious complications.
The uvea has three connected sections that work together to keep the eye healthy and functioning. The iris, the colored ring at the front of the eye, controls how much light enters. The ciliary body sits just behind the iris and produces aqueous humor, the clear fluid that nourishes structures in the front of the eye. The choroid is a layer of blood vessels that delivers oxygen and nutrients to the outer layers of the retina.
Because all three structures form one continuous layer, inflammation in one area can spread easily to the others. When all three sections are inflamed simultaneously, with no single area more affected than the rest, the condition is called panuveitis or diffuse uveitis.
Uveitis is classified by where it occurs. Anterior uveitis affects the iris and front of the eye. Intermediate uveitis targets the middle zone, including the vitreous gel. Posterior uveitis involves the choroid and retina at the back of the eye. Panuveitis stands apart because it involves all of these areas at once.
This widespread involvement makes panuveitis particularly challenging. Because every part of the uvea is affected, patients can experience a broader mix of symptoms, a greater risk of complications, and a need for more comprehensive treatment compared to uveitis confined to one area.
Several types of triggers can lead to panuveitis. Infectious causes include bacteria, viruses, fungi, and parasites. Autoimmune diseases, where the immune system mistakenly attacks the body's own tissues, are another common source. In many cases, no specific cause is identified, and the condition is classified as idiopathic.
Two systemic conditions are especially linked to panuveitis:
- Behcet disease is a multisystem condition marked by recurring mouth sores, genital ulcers, and panuveitis. It is most common in patients from Turkey, the Middle East, and parts of Asia.
- Sarcoidosis is a chronic disease that produces clusters of inflammatory cells called granulomas. It is one of the most frequently identified systemic causes of panuveitis and is more common in colder climates and among people of Black ethnicity.
Who Is Affected and What Raises the Risk
Panuveitis can affect people of different ages, backgrounds, and health histories. Certain personal and medical factors, however, do raise the likelihood of developing this condition. Understanding these risk factors can help guide earlier screening and care.
Uveitis in all its forms is a significant cause of vision loss, accounting for five to twenty percent of blindness in the United States and Europe, and a higher proportion in developing countries. Panuveitis is less common in children than in adults, but it still makes up a meaningful portion of pediatric uveitis cases and requires prompt attention in younger patients because their developing eyes are especially vulnerable to complications.
The risk of developing infectious panuveitis increases with age. Women face a slightly higher risk than men overall. Certain ethnic backgrounds carry added risk depending on the underlying cause. Behcet disease is most prevalent in populations from Turkey and parts of Asia, while sarcoidosis-related panuveitis is more common among people of Black ethnicity.
Certain health conditions significantly increase the chance of developing panuveitis. HIV infection, rheumatologic diseases such as lupus and rheumatoid arthritis, and existing autoimmune conditions like sarcoidosis and Vogt-Koyanagi-Harada syndrome are among the most well-established risk factors.
Other factors that may contribute to risk include:
- A history of ocular trauma or eye surgery
- Exposure to infectious agents, particularly in people with weakened immune systems
- Genetic predisposition, especially in populations with higher rates of associated systemic diseases
Symptoms and Warning Signs
Because panuveitis affects all parts of the uvea at once, it can produce a wide range of symptoms, some of which overlap with other eye conditions. Recognizing these signs early and knowing when to seek urgent care can make a meaningful difference in protecting your vision.
Most patients experience several symptoms at the same time, though severity varies from person to person. The most frequently reported symptoms reflect involvement of both the front and back of the eye.
- Eye pain ranging from mild aching to severe discomfort
- Photophobia, meaning increased sensitivity to light
- Blurred or reduced vision
- Floaters, which appear as spots, threads, or cobwebs drifting across your field of vision
- Eye redness
Certain symptoms require immediate evaluation and should not be waited out at home. Sudden severe eye pain, significant vision loss, a sudden increase in floaters, flashes of light, or a curtain or shadow moving across your vision all warrant an urgent visit to a retina specialist or an emergency room.
A particularly severe form called seasonal hyperacute panuveitis (SHAPU) can cause rapid and profound vision loss in one eye within a single week. This condition is an important cause of blindness in one eye in children. Any child with sudden eye pain and sudden vision loss should receive emergency ophthalmologic evaluation without delay.
How Panuveitis Is Diagnosed
Diagnosing panuveitis involves a detailed examination of both the front and back of the eye, combined with imaging and laboratory testing. Because the condition is often linked to diseases elsewhere in the body, investigation extends beyond the eye itself.
Evaluation begins with a comprehensive eye exam using a slit lamp, a specialized microscope that allows the specialist to examine the eye in detail. The specialist looks for inflammatory cells floating in the aqueous humor (the fluid inside the front of the eye), deposits called keratic precipitates on the inner surface of the cornea, and signs of inflammation in the back of the eye such as vitreous haze and choroidal involvement.
Advanced imaging provides a more complete picture of how panuveitis is affecting the eye. Optical coherence tomography (OCT) produces detailed cross-sectional images of the retina and can detect complications such as cystoid macular edema, which is swelling in the central part of the retina that often causes vision loss. Fluorescein angiography uses a special dye to evaluate blood flow and leakage in the retinal blood vessels, helping to guide treatment decisions.
Identifying what is driving the inflammation is critical for choosing the right treatment. Blood tests may check for sarcoidosis, Behcet disease, tuberculosis, syphilis, and a range of autoimmune markers. Chest imaging may be ordered to look for evidence of sarcoidosis or tuberculosis. In some cases, a small sample of fluid from inside the eye is analyzed to identify infectious organisms.
When a systemic condition is suspected, the specialist may coordinate with a rheumatologist, infectious disease physician, or other specialist. In a significant number of cases, no underlying cause is found despite thorough testing. These idiopathic cases still require treatment to control inflammation and protect vision.
Treatment Options
Treatment for panuveitis is tailored to the individual patient based on the cause of inflammation, disease severity, and overall health. A stepwise approach is typical, beginning with corticosteroids and advancing to other therapies when long-term management is needed.
Corticosteroids are the standard first-line treatment for acute panuveitis. They can be delivered as topical eye drops for inflammation in the front of the eye, as periocular injections (placed around the eye) to reach deeper tissues, or as oral medications like prednisone when inflammation is severe or involves both eyes.
While corticosteroids work quickly to reduce inflammation, long-term use carries meaningful risks. These include elevated eye pressure that can lead to glaucoma, cataract formation, weight gain, elevated blood sugar, and bone thinning. For this reason, the goal is to use corticosteroids to gain initial control and then transition to therapies that do not carry the same long-term risks.
Patients who require long-term treatment are typically transitioned to immunosuppressive medications that allow inflammation to be controlled without continued dependence on steroids. Commonly used drugs include methotrexate, mycophenolate mofetil, and azathioprine.
These medications work by broadly reducing the immune system's inflammatory activity. They require regular blood monitoring to check liver function, kidney function, and blood cell counts. It often takes several weeks to months before these drugs reach their full effect, so corticosteroids may be continued during the transition period.
Biologic medications target specific pathways in the immune system rather than broadly suppressing it. One of the most important targets is tumor necrosis factor-alpha (TNF-alpha), a key protein involved in inflammation. Adalimumab is a biologic medication that blocks TNF-alpha and is approved by the FDA for adults with noninfectious intermediate, posterior, and panuveitis. Based on results of the SYCAMORE study, the approval was expanded to include children ages two and older. It is given as an injection under the skin, typically every two weeks.
For patients with chronic noninfectious panuveitis, implants that release medication gradually inside the eye offer a way to maintain long-term local therapy. Retisert is a surgically placed implant that delivers a steroid called fluocinolone acetonide continuously for approximately three years and is approved for noninfectious intermediate uveitis, posterior uveitis, and panuveitis.
Iluvien is a smaller implant that is injected rather than surgically placed and delivers continuous low-dose steroid therapy for up to 36 months. Xipere is an injectable suspension delivered through a suprachoroidal route, placing medication in the space between the choroid and sclera to achieve high drug concentrations at the retina while potentially reducing the risk of steroid-related side effects.
Research into new approaches to treating panuveitis is ongoing. Brepocitinib, an oral medication that targets specific inflammatory pathways called TYK2 and JAK1, is currently in a Phase III clinical trial for noninfectious uveitis. It received Fast Track Designation from the FDA in 2024, which is designed to speed development and review of drugs for serious conditions. If approved, it could provide a new oral treatment option for patients managing this challenging disease.
What to Expect Living with Panuveitis
Managing panuveitis is an ongoing process that extends well beyond initial treatment. Understanding what the recovery period looks like, what complications to watch for, and how to protect your vision over time helps patients stay engaged in their own care.
Initial corticosteroid therapy may bring noticeable improvement within days to weeks. Transitioning to steroid-sparing medications takes longer, often several months before full effectiveness is achieved. During this period, frequent follow-up visits allow your specialist to monitor inflammation levels, adjust medications, and catch early signs of complications. As the condition stabilizes, the interval between visits typically lengthens.
Panuveitis carries a real risk of vision-threatening complications, particularly when inflammation is not well controlled. Cystoid macular edema (swelling of the central retina) is one of the most common causes of vision loss in patients with uveitis. Cataracts and elevated eye pressure leading to glaucoma can result from both the inflammation itself and from corticosteroid treatment.
Other complications that may develop include:
- Band keratopathy, a calcium deposit on the surface of the cornea
- Vitreous opacities, meaning clumps of inflammatory cells in the gel of the eye
- Synechiae, which are abnormal adhesions between the iris and the lens or cornea
- Retinal scarring from prolonged or untreated inflammation
The prognosis for panuveitis depends on the underlying cause, how severe the inflammation is, and how quickly treatment begins. Some patients achieve long-term remission and are eventually able to taper off medications under close supervision. Others require ongoing therapy to prevent flare-ups and preserve vision. When panuveitis is caused by a treatable infection, controlling the infection often leads to resolution of the eye inflammation. Patients with chronic autoimmune-related panuveitis typically need long-term management with immunosuppressive or biologic therapy.
Managing Panuveitis Day to Day
Living with a chronic inflammatory eye condition involves more than taking medication. Learning to recognize early warning signs, staying consistent with treatment, and coordinating care with multiple specialists all play an important role in protecting your vision over the long term.
Panuveitis can follow a relapsing and remitting pattern, meaning periods of stability can be interrupted by flare-ups. Early signs often include increasing light sensitivity, mild blurring, or new floaters. Contacting your specialist at the first sign of a flare, rather than waiting, allows treatment to begin before inflammation causes cumulative damage.
Staying consistent with your medication schedule is critical. Missing doses of immunosuppressive or biologic medications raises the risk of recurrence. If side effects become a problem, discuss them with your specialist before making any changes to your regimen on your own.
Because panuveitis is frequently connected to systemic diseases, many patients benefit from a team approach to care. A rheumatologist may manage an underlying autoimmune condition. An infectious disease specialist may be involved if an infection is driving the inflammation. Your primary care physician should be aware of your diagnosis and any medications you are taking.
Clear communication between your retina specialist and other treating physicians helps ensure that all aspects of your health are being managed together and that treatments do not conflict with one another.
Sunglasses can ease photophobia, especially during flare-ups or on bright days. Keeping every scheduled eye appointment matters even when your eyes feel fine, because inflammation can be active without obvious symptoms. Maintaining a healthy lifestyle, including regular physical activity, a balanced diet, and adequate sleep, supports your overall immune health and complements your medical treatment.
Frequently Asked Questions
These questions address common points of uncertainty that patients often raise after their diagnosis, helping to guide decisions and set realistic expectations.
It depends on what is causing the inflammation. When an identifiable infection is the source, successfully treating that infection can resolve the eye inflammation. In autoimmune or idiopathic cases, however, panuveitis is typically a chronic condition that is managed over time rather than permanently eliminated. The focus of care shifts to controlling inflammation, preventing complications, and maintaining the best vision possible.
Stopping medication on your own, even if your eyes feel fine, carries a real risk of triggering a flare-up. Panuveitis can remain active at a subclinical level even when symptoms are absent, and abrupt discontinuation can allow inflammation to return quickly and more aggressively. Any decision to reduce or stop medication should be made gradually and under direct guidance from your specialist.
Panuveitis can involve one or both eyes, and whether both are affected often depends on the underlying cause. Systemic conditions such as sarcoidosis and Behcet disease are more likely to produce bilateral involvement. Even when only one eye is currently affected, your specialist will monitor both eyes at each visit, since inflammation can develop in the second eye over time.
All long-term immunosuppressive therapies carry some level of risk, and those risks vary by medication type. Corticosteroids used over extended periods can contribute to cataracts, elevated eye pressure, bone thinning, and blood sugar changes. Traditional immunosuppressives such as methotrexate and mycophenolate mofetil require regular blood tests to monitor liver and kidney function. Biologic agents like adalimumab may lower resistance to certain infections. Your specialist will weigh these risks against the serious risk of uncontrolled inflammation, which can cause permanent, irreversible vision loss.
Yes, panuveitis does occur in children, though it is less common than in adults. Prompt diagnosis and treatment are especially important in pediatric patients because their developing eyes are more vulnerable to complications from prolonged inflammation. Adalimumab is an approved treatment option for children ages two and older with noninfectious uveitis, and its approval was supported by clinical trial data specifically in pediatric patients. A pediatric ophthalmologist and retina specialist working together can provide coordinated care for children with this condition.
Sudden vision changes, including a rapid increase in floaters, flashes of light, a curtain or shadow across your vision, or abrupt vision loss, should be treated as an urgent situation regardless of whether you have a known diagnosis of panuveitis. These symptoms can signal a serious flare or a vision-threatening complication that requires immediate evaluation. Contact a retina specialist the same day or go to an emergency room rather than waiting to see whether symptoms resolve on their own.
Expert Panuveitis Care at Rhode Island Eye Institute
At Rhode Island Eye Institute, our fellowship-trained retina specialists have the expertise and advanced diagnostic tools to evaluate, diagnose, and manage panuveitis with precision and care. We understand how much is at stake when inflammation threatens your vision, and we are committed to building a treatment plan tailored to your individual situation. If you are experiencing symptoms or have been referred for a uveitis evaluation, we welcome you to connect with our team and take the next step toward protecting your sight.